Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dipipanone is a strong opioid analgesic used for the management of moderate to severe pain, particularly in situations where morphine is indicated but cannot be used due to allergy or intolerance. It is structurally related to methadone and belongs to the 4,4-diphenylheptane-3-one class of opioids. Dipipanone acts primarily by binding to mu-opioid receptor in the central nervous system, altering both the perception and emotional response to pain. It has a rapid onset and shorter duration of action compared with methadone. The drug can cause dependence and withdrawal symptoms if discontinued abruptly. Dipipanone is most commonly available as an oral formulation, often combined with cyclizine (as in Diconal) for additional antiemetic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dipipanone.